Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer

Summary

Cadonilimab, a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumors, including cervical cancer, lung cancer, gastric/gastroesophageal junction cancer, liver cancer and nasopharyngeal cancer. Cadonilimab was approved in China in June 2022 for use in patients with relapsed or metastatic cervical cancer who have progressed on or after platinum-based chemotherapy. The clinicopathological data of patients with persistent, recurrent or metastatic cervical cancer treated with Cadonilimab were collected, and medical images (magnetic resonance, CT, etc.) before and after treatment were followed up, and the efficacy was evaluated according to RECIST standards. The incidence and severity of adverse events and clinically significant abnormal laboratory test results were collected to evaluate the safety of the drug. Survival benefit analysis is conducted based on the patient's survival time and medical expenses.

Eligibility

Inclusion Criteria:

* •Persistent, recurrent or metastatic cervical cancer;

  * The pathological types are squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma;
  * No combination with other multiple primary cancers;
  * MRI before treatment Or CT examination, according to RECIST evaluation standards, there is at least one measurable lesion;
  * ECOG score 0-1 points.
  * Subjects gave informed consent, voluntarily cooperated with clinical follow-up, and signed informed consent forms.

Exclusion Criteria:

* Patients with other histopathological types of cervical cancer, such as small cell carcinoma, clear cell carcinoma, sarcoma, etc.;

  * Previous treatment with immune checkpoint inhibitors;
  * There are drug contraindications, such as liver function Insufficiency, renal insufficiency, etc.
  * The patient withdraws the informed consent;
  * The researcher determines that the patient is not suitable to participate in this clinical study.

Conditions2

Interventions1

Related trials

• A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma — Akeso
• A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) — Akeso
• A Study of Ivonescimab in First-Line ES-SCLC — Akeso
• A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. — Shanghai Pharmaceuticals Holding Co., Ltd
• AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy — Fudan University
• AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer — Harbin Medical University
• Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative — Qian Chu
• Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients — Zhejiang Cancer Hospital

Browse More Trials